Clinical Trial Update: Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator [NA]

View source ↗

Summary

Ongoing study aims to optimize beta blocker dosing in women who are using a wearable cardioverter defibrillator for cardiomyopathy and heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiomyopathy
• Heart Failure

Drugs mentioned

• Beta-blocker

Snippet

Sponsor: Zoll Medical Corporation | Conditions: Cardiomyopathies, Heart Failure | NA | Status: RECRUITING